Function Blocking Antibodies to Neuropilin-1 Generated from a Designed Human Synthetic Antibody Phage Library

Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Bradbury, 2004, Antibodies from phage antibody libraries, J. Immunol. Methods, 290, 29, 10.1016/j.jim.2004.04.007 Lipovsek, 2004, In-vitro protein evolution by ribosome display and mRNA display, J. Immunol. Methods, 290, 51, 10.1016/j.jim.2004.04.008 Feldhaus, 2004, Yeast display of antibody fragments: a discovery and characterization platform, J. Immunol. Methods, 290, 69, 10.1016/j.jim.2004.04.009 Hoogenboom, 2005, Selecting and screening recombinant antibody libraries, Nature Biotechnol., 23, 1105, 10.1038/nbt1126 Barbas, 1993, High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site, Proc. Natl Acad. Sci. USA, 90, 10003, 10.1073/pnas.90.21.10003 Knappik, 2000, Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides, J. Mol. Biol., 296, 57, 10.1006/jmbi.1999.3444 Sheets, 1998, Efficient construction of a large non-immune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens, Proc. Natl Acad. Sci. USA, 95, 6157, 10.1073/pnas.95.11.6157 de Haard, 1999, A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies, J. Biol. Chem., 274, 18218, 10.1074/jbc.274.26.18218 Sidhu, 2004, Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions, J. Mol. Biol., 338, 299, 10.1016/j.jmb.2004.02.050 Lee, 2004, High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold, J. Mol. Biol., 340, 1073, 10.1016/j.jmb.2004.05.051 Carter, 1992, Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc. Natl Acad. Sci. USA, 89, 4285, 10.1073/pnas.89.10.4285 Lee, 2004, Bivalent antibody phage display mimics natural immunoglobulin, J. Immunol. Methods, 284, 119, 10.1016/j.jim.2003.11.001 Liang, 2006, Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF, J. Biol. Chem., 281, 951, 10.1074/jbc.M508199200 Mian, 1991, Structure, function and properties of antibody binding sites, J. Mol. Biol., 217, 133, 10.1016/0022-2836(91)90617-F He, 1997, Neuropilin is a receptor for the axonal chemorepellent Semaphorin III, Cell, 90, 739, 10.1016/S0092-8674(00)80534-6 Chen, 1997, Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III, Neuron, 19, 547, 10.1016/S0896-6273(00)80371-2 Kolodkin, 1997, Neuropilin is a semaphorin III receptor, Cell, 90, 753, 10.1016/S0092-8674(00)80535-8 Soker, 1998, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor, Cell, 92, 735, 10.1016/S0092-8674(00)81402-6 Kitsukawa, 1997, Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice, Neuron, 19, 995, 10.1016/S0896-6273(00)80392-X Kawasaki, 1999, A requirement for neuropilin-1 in embryonic vessel formation, Development, 126, 4895, 10.1242/dev.126.21.4895 Ferrara, 2005, VEGF as a therapeutic target in cancer, Oncology, 69, 11, 10.1159/000088479 Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483 Kerbel, 2001, Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches, Cancer Metastasis Rev., 20, 79, 10.1023/A:1013172910858 Jain, 2006, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Naure Clin. Pract. Oncol., 3, 24, 10.1038/ncponc0403 Barbas, 1992, Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem, Proc. Natl Acad. Sci. USA, 89, 4457, 10.1073/pnas.89.10.4457 Chothia, 1989, Conformations of immunoglobulin hypervariable regions, Nature, 342, 877, 10.1038/342877a0 Wu, 1993, Length distribution of CDRH3 in antibodies, Proteins:Struct.Funct. Genet., 16, 1, 10.1002/prot.340160102 Gu, 2002, Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165, J. Biol. Chem., 277, 18069, 10.1074/jbc.M201681200 Gallop, 1994, Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries, J. Med. Chem., 37, 1233, 10.1021/jm00035a001 Ferrara, 2005, Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy, Biochem. Biophys. Res. Commun., 333, 328, 10.1016/j.bbrc.2005.05.132 Fellouse, 2004, Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition, Proc. Natl Acad. Sci. USA, 101, 12467, 10.1073/pnas.0401786101 Pan, Q., Chantery, Y., Liang, WC., Stawicki, S., Mak, J., Rathore, N. et al. (2006). Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer cell, in press. Kunkel, 1991, Efficient site-directed mutagenesis using uracil-containing DNA, Methods Enzymol., 204, 125, 10.1016/0076-6879(91)04008-C Presta, 1993, Humanization of an antibody directed against IgE, J. Immunol., 151, 2623, 10.4049/jimmunol.151.5.2623